Development of a biotechnology application to facilitate individualized drug therapy in neonatology
Financing Ministerio de Ciencia e Innovación (Spain) – Programa INNPACTO (IPT-090000-2010-2)
Duration: October 2010 – December 2013
The DynaPUMP NEO consortium is composed of two Spanish SMEs: Dynakin S.L and Anaxomics Biotech and one Spanish university: Universidad del País Vasco (Pharmacokinetics Group).
Drug prescription for children population is much more complex than for adult patients. Children differ from adults in response to drugs. These differences may be due to changes in the pharmacokinetic (PK) and / or pharmacodynamics (PD) among children and adults as well as differences between children of different ages due to “changes of development” in children.
The goal is therefore, to obtain data from children that allow us to study these “changes of development” to assess factors that influence the PK and PD of the drugs. Once known these factors, the objective is to develop predictive models that ensure a more rational and effective drug dosing in each particular individual according to their characteristics (among which is the degree of maturity of organs and systems).
The specific objectives of the project are
Creation of a biotechnology application that provides a personalized pharmacotherapy in neonatal population.
This task consist in a retrospective data collection of drugs that are monitored in neonatal ICUs (collaboration with University Hospital Laussane and Iridessa), the identification of differential expression patterns of drugs behavior in newborns and the subsequent development of a predictive model for the individualization of neonatal pharmacotherapy.
Design of an intelligent dosage device in neonatology.
Selection of the most important drugs to be included in the dosage devices to design an intelligence dosage device prototype.